CA2562016A1 - Nucleic acid based assays for identification of fc receptor polymorphisms - Google Patents

Nucleic acid based assays for identification of fc receptor polymorphisms Download PDF

Info

Publication number: CA2562016A1
Authority: CA; Canada
Prior art keywords: gamma; primers; genotype; nucleic acids; combination
Prior art date: 2004-04-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002562016A

Other languages

English (en)

French (fr)

Inventor

Pablo G. Garcia

Susan E. Wilson

Gene Guozhong Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-07

Filing date

2004-12-22

Publication date

2005-11-03

2004-12-22 Application filed by Individual filed Critical Individual

2005-11-03 Publication of CA2562016A1 publication Critical patent/CA2562016A1/en

Status Abandoned legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 89
102000039446 nucleic acids Human genes 0.000 title claims abstract description 82
108020004707 nucleic acids Proteins 0.000 title claims abstract description 82
102000054765 polymorphisms of proteins Human genes 0.000 title claims abstract description 17
238000003556 assay Methods 0.000 title abstract description 39
108010087819 Fc receptors Proteins 0.000 title description 3
102000009109 Fc receptors Human genes 0.000 title description 3
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 77
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 51
238000012163 sequencing technique Methods 0.000 claims abstract description 49
230000003321 amplification Effects 0.000 claims abstract description 43
238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 43
238000003205 genotyping method Methods 0.000 claims abstract description 26
239000013615 primer Substances 0.000 claims description 141
238000000034 method Methods 0.000 claims description 99
125000003729 nucleotide group Chemical group 0.000 claims description 68
239000002773 nucleotide Substances 0.000 claims description 67
239000003155 DNA primer Substances 0.000 claims description 25
239000012472 biological sample Substances 0.000 claims description 16
230000000692 anti-sense effect Effects 0.000 claims description 9
238000013518 transcription Methods 0.000 claims description 9
230000035897 transcription Effects 0.000 claims description 9
238000012408 PCR amplification Methods 0.000 claims description 8
230000001404 mediated effect Effects 0.000 claims description 8
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 7
239000007850 fluorescent dye Substances 0.000 claims description 6
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 5
WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 claims description 5
101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 claims description 3
101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
238000003757 reverse transcription PCR Methods 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 description 81
238000003752 polymerase chain reaction Methods 0.000 description 67
108020004414 DNA Proteins 0.000 description 60
239000000047 product Substances 0.000 description 48
239000000523 sample Substances 0.000 description 46
238000006243 chemical reaction Methods 0.000 description 36
108091032973 (ribonucleotides)n+m Proteins 0.000 description 34
239000002585 base Substances 0.000 description 28
102000040430 polynucleotide Human genes 0.000 description 25
108091033319 polynucleotide Proteins 0.000 description 25
239000002157 polynucleotide Substances 0.000 description 25
239000000203 mixture Substances 0.000 description 22
230000000295 complement effect Effects 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
102100031780 Endonuclease Human genes 0.000 description 12
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
230000002441 reversible effect Effects 0.000 description 12
230000027455 binding Effects 0.000 description 11
102000054766 genetic haplotypes Human genes 0.000 description 11
102000053602 DNA Human genes 0.000 description 10
239000002253 acid Substances 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
-1 phosphotriesters Chemical class 0.000 description 9
150000007513 acids Chemical class 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000011282 treatment Methods 0.000 description 7
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 6
101710163270 Nuclease Proteins 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
239000012634 fragment Substances 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 5
102000004594 DNA Polymerase I Human genes 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 5
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 5
108020005187 Oligonucleotide Probes Proteins 0.000 description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
239000000975 dye Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
239000002751 oligonucleotide probe Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
108700028369 Alleles Proteins 0.000 description 4
241000713838 Avian myeloblastosis virus Species 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
238000010804 cDNA synthesis Methods 0.000 description 4
230000000536 complexating effect Effects 0.000 description 4
230000001351 cycling effect Effects 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000002987 primer (paints) Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000002194 synthesizing effect Effects 0.000 description 4
239000001226 triphosphate Substances 0.000 description 4
235000011178 triphosphate Nutrition 0.000 description 4
239000004474 valine Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000701832 Enterobacteria phage T3 Species 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
238000007834 ligase chain reaction Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
230000002974 pharmacogenomic effect Effects 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
238000002944 PCR assay Methods 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
101100244535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) POP6 gene Proteins 0.000 description 2
101100244540 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pop7 gene Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229910052796 boron Inorganic materials 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
150000008298 phosphoramidates Chemical class 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
230000000379 polymerizing effect Effects 0.000 description 2
230000037452 priming Effects 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
101150066838 12 gene Proteins 0.000 description 1
101150025032 13 gene Proteins 0.000 description 1
101150082072 14 gene Proteins 0.000 description 1
101150029062 15 gene Proteins 0.000 description 1
101150076401 16 gene Proteins 0.000 description 1
101150016096 17 gene Proteins 0.000 description 1
101150078635 18 gene Proteins 0.000 description 1
101150040471 19 gene Proteins 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
108010037497 3'-nucleotidase Proteins 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
101150096316 5 gene Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229930182476 C-glycoside Natural products 0.000 description 1
150000000700 C-glycosides Chemical class 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
229930182846 D-asparagine Natural products 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101150026303 HEX1 gene Proteins 0.000 description 1
101001122597 Homo sapiens Ribonuclease P protein subunit p20 Proteins 0.000 description 1
108010073807 IgG Receptors Proteins 0.000 description 1
102000009490 IgG Receptors Human genes 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101710141452 Major surface glycoprotein G Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
102100028674 Ribonuclease P protein subunit p20 Human genes 0.000 description 1
241001468001 Salmonella virus SP6 Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
241000205180 Thermococcus litoralis Species 0.000 description 1
241000589500 Thermus aquaticus Species 0.000 description 1
241000589499 Thermus thermophilus Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000002820 assay format Methods 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
YDQXYRCYDMRJGD-UHFFFAOYSA-N chloroform;phenol;thiocyanic acid Chemical compound SC#N.ClC(Cl)Cl.OC1=CC=CC=C1 YDQXYRCYDMRJGD-UHFFFAOYSA-N 0.000 description 1
238000010367 cloning Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
108700020302 erbB-2 Genes Proteins 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
150000002540 isothiocyanates Chemical group 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000000746 purification Methods 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000004054 semiconductor nanocrystal Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
VVLFAAMTGMGYBS-UHFFFAOYSA-M sodium;4-[[4-(ethylamino)-3-methylphenyl]-(4-ethylimino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-3-sulfobenzenesulfonate Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S(O)(=O)=O)=C1C=C(C)C(=NCC)C=C1 VVLFAAMTGMGYBS-UHFFFAOYSA-M 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002562016A 2004-04-07 2004-12-22 Nucleic acid based assays for identification of fc receptor polymorphisms Abandoned CA2562016A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US56064904P	2004-04-07	2004-04-07
US60/560,649		2004-04-07
PCT/US2004/043726 WO2005102379A2 (en)	2004-04-07	2004-12-22	Nucleic acid based assays for identification of fc receptor polymorphisms

Publications (1)

Publication Number	Publication Date
CA2562016A1 true CA2562016A1 (en)	2005-11-03

Family

ID=35197498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002562016A Abandoned CA2562016A1 (en)	2004-04-07	2004-12-22	Nucleic acid based assays for identification of fc receptor polymorphisms

Country Status (10)

Country	Link
EP (1)	EP1732939A4 (pt)
JP (1)	JP2007532110A (pt)
KR (1)	KR20070004082A (pt)
CN (1)	CN1976942A (pt)
AU (1)	AU2004318681A1 (pt)
BR (1)	BRPI0418722A (pt)
CA (1)	CA2562016A1 (pt)
IL (1)	IL178333A0 (pt)
RU (1)	RU2006138865A (pt)
WO (1)	WO2005102379A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090181016A1 (en) *	2005-11-30	2009-07-16	University Of Southern California	FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
AU2008205543A1 (en)	2007-01-18	2008-07-24	University Of Southern California	Genetic markers for predicting responsiveness to combination therapy
WO2009026502A1 (en) *	2007-08-22	2009-02-26	Wyeth	Nested pcr-based method for specific genotyping of the fc-gamma receptor iiia gene
WO2015054731A1 (en) *	2013-10-15	2015-04-23	Conexio Genomics Pty Ltd	Major histocompatibility complex single nucleotide polymorphisms
TW202146644A (zh) *	2020-01-16	2021-12-16	育世博生物科技股份有限公司	一種新穎的ｃｄ１６陽性自然殺手細胞及一種培養ｃｄ１６陽性自然殺手細胞的方法
CN114277149B (zh) *	2021-12-30	2023-09-22	苏州方科生物科技有限公司	一种检测cd16a基因多态性的试剂盒及其应用和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639611A (en) *	1988-12-12	1997-06-17	City Of Hope	Allele specific polymerase chain reaction
WO2003035904A2 (en) *	2001-10-19	2003-05-01	Centre Hospitalier Regional Et Universitaire De Tours	Methods and compositions to evaluate antibody treatment response

2004
- 2004-12-22 EP EP04815738A patent/EP1732939A4/en not_active Withdrawn
- 2004-12-22 AU AU2004318681A patent/AU2004318681A1/en not_active Abandoned
- 2004-12-22 JP JP2007507303A patent/JP2007532110A/ja active Pending
- 2004-12-22 BR BRPI0418722-9A patent/BRPI0418722A/pt not_active IP Right Cessation
- 2004-12-22 WO PCT/US2004/043726 patent/WO2005102379A2/en not_active Ceased
- 2004-12-22 KR KR1020067022960A patent/KR20070004082A/ko not_active Withdrawn
- 2004-12-22 RU RU2006138865/13A patent/RU2006138865A/ru not_active Application Discontinuation
- 2004-12-22 CA CA002562016A patent/CA2562016A1/en not_active Abandoned
- 2004-12-22 CN CNA2004800428432A patent/CN1976942A/zh active Pending
2006
- 2006-09-27 IL IL178333A patent/IL178333A0/en unknown

Also Published As

Publication number	Publication date
CN1976942A (zh)	2007-06-06
WO2005102379A3 (en)	2006-02-16
WO2005102379A2 (en)	2005-11-03
IL178333A0 (en)	2007-02-11
EP1732939A2 (en)	2006-12-20
KR20070004082A (ko)	2007-01-05
BRPI0418722A (pt)	2007-09-11
JP2007532110A (ja)	2007-11-15
RU2006138865A (ru)	2008-05-20
EP1732939A4 (en)	2008-09-17
AU2004318681A1 (en)	2005-11-03

Legal Events

Date	Code	Title	Description
2010-12-22	FZDE	Discontinued

Publication	Publication Date	Title
US20250138014A1 (en)	2025-05-01	Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
WO2012061814A1 (en)	2012-05-10	Pcr primers and methods for rapid and specific genotyping
US10801078B2 (en)	2020-10-13	Methods and compositions for detecting BK virus
AU2015358251A1 (en)	2017-06-29	Methods and reagents for detecting neisseria gonorrhoeae and its antimicrobial resistance determinants
CN101182585B (zh)	2010-06-09	一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒
MXPA04012501A (es)	2005-02-17	Identificacion de oligonucleotidos para la captura, deteccion y cuatificacion de acido nucleico viral de la hepatitis a.
JP2005505289A (ja)	2005-02-24	Ｂ型肝炎ウイルスｄｎａの捕獲、検出および定量のためのオリゴヌクレオチドの同定
CA2562016A1 (en)	2005-11-03	Nucleic acid based assays for identification of fc receptor polymorphisms
JP6153515B2 (ja)	2017-06-28	Ｈｌａ−ａ＊２４：０２を検出する方法、及び検出キット
CN102344970B (zh)	2013-01-23	同时检测人cmv和bk病毒dna的引物序列及定量检测试剂盒
EP2217724A1 (en)	2010-08-18	Jak2 mutations
Ou et al.	2005	Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method
KR20130113046A (ko)	2013-10-15	간질환 진단용 마커 및 이의 용도
MXPA06011476A (en)	2007-04-20	Nucleic acid based assays for identification of fc receptor polymorphisms
KR20160148807A (ko)	2016-12-27	장 베체트병 진단용 바이오마커 및 이의 용도
CN104387457A (zh)	2015-03-04	慢性乙型和丁型肝炎病毒肝细胞受体编码基因slc10a1的新突变蛋白、编码基因及其应用
EP1848821A1 (en)	2007-10-31	Polynucleotide associated with breast cancer comprising single nucleotide polymorphism, microarray and diagnostic kit comprising the same and method for diagnosing breast cancer using the same
AU2012261529B2 (en)	2016-11-03	Methods and compositions for detecting BK virus
JP2007054002A (ja)	2007-03-08	メタボリックシンドロームの診断および予防
HK1115613B (en)	2016-04-22	Methods and compositions for detecting bk virus
JP2011050377A (ja)	2011-03-17	新規ｈｌａ−ｄｒｂ１遺伝子およびその用途